Solstein Capital’s Charles River Laboratories CRL Stock Holding History

Solstein Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$104K	Hold	600	–	–	0.04%	172
2025 Q4	$120K	Hold	600	–	–	0.05%	155
2025 Q3	$93.9K	Sell	600 -114	-16%	-$18.1K	0.02%	159
2025 Q2	$108K	Hold	714	–	–	0.06%	148
2025 Q1	$107K	Hold	714	–	–	0.06%	125
2024 Q4	$132K	Hold	714	–	–	0.07%	119
2024 Q3	$141K	Hold	714	–	–	0.07%	118
2024 Q2	$147K	Hold	714	–	–	0.1%	109
2024 Q1	$193K	Hold	714	–	–	0.13%	92
2023 Q4	$169K	Hold	714	–	–	0.12%	97
2023 Q3	$140K	Hold	714	–	–	0.12%	101
2023 Q2	$150K	Buy	714 +114	+19%	+$22.7K	0.13%	97
2023 Q1	$121K	Hold	600	–	–	0.11%	107
2022 Q4	$131K	Hold	600	–	–	0.11%	120
2022 Q3	$118K	Hold	600	–	–	0.1%	106
2022 Q2	$128K	Sell	600 -200	-25%	-$48.9K	0.1%	121
2022 Q1	$227K	Hold	800	–	–	0.15%	104
2021 Q4	$301K	Hold	800	–	–	0.18%	108
2021 Q3	$330K	Buy	+800	New	+$332K	0.19%	103

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Solstein Capital's CRL Position: Q1 2026 in Review

Solstein Capital held its Charles River Laboratories (CRL) position steady in Q1 2026 at 600 shares worth $104K. The position accounts for 0.04% of the portfolio, ranked #172.

Solstein Capital first reported a position in CRL in Q3 2021 and has held it in 19 quarters since. The position peaked at $330K in Q3 2021. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Solstein Capital held 600 shares of Charles River Laboratories worth $104K as of Q1 2026.
Solstein Capital left its Charles River Laboratories share count unchanged in Q1 2026.
Charles River Laboratories made up 0.04% of Solstein Capital's portfolio in Q1 2026, its #172 holding.
Solstein Capital first reported a position in Charles River Laboratories in Q3 2021 and has held it in 19 quarters since.
Solstein Capital's Charles River Laboratories position peaked at $330K in Q3 2021.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Solstein Capital's 13F filing for Q1 2026, filed 14 May 2026.